US · AKRO
Akero Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- South San Francisco, CA 94080
- Website
- akerotx.com
Price · as of 2024-12-31
—
Market cap 4.32B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $24.41 | ||||
| 2020 | $32.98 | ||||
| 2021 | $14.21 | ||||
| 2022 | $41.35 | ||||
| 2023 | $31.18 | ||||
| 2024 | $42.12 |
AI valuation
Our deep-learning model estimates Akero Therapeutics, Inc.'s (AKRO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AKRO | Akero Therapeutics, Inc. | $54.05 | 4.32B | — | — | — | — | -11.22 | 3.77 | — | -7.43 | -37.70 | 3.77 | 0.00% | — | — | -39.22% | -1042.60% | -35.85% | 0.05 | -61.14 | 19.38 | 18.69 | 1.06 | 2976.00% | — | 5898.00% | -8.17% | -5.79 | -844.19% | 0.00% | 0.00% | 3.41% | -7.43 | -9.18 | — | 20.91 |
| ACAD | ACADIA Pharmaceuticals In… | $22.33 | 3.77B | +92% | +56% | -50% | +136% | 12.85 | 3.97 | 3.04 | 22.02 | — | 4.75 | 91.46% | 24.10% | 23.64% | 38.89% | 513.41% | 23.39% | 0.07 | — | 2.38 | 2.18 | -2.67 | -46757.00% | 3185.00% | -77327.00% | 5.40% | 0.40 | 398.52% | 0.00% | 0.00% | 4.68% | 9.56 | 14.03 | 2.30 | 3.24 |
| ACLX | Arcellx, Inc. | $87.51 | 4.85B | -25% | — | — | — | -28.05 | — | — | -31.38 | -27.10 | — | 0.00% | — | — | -100.68% | 644.58% | -39.69% | — | -10.45 | — | — | 0.00 | 10350.00% | -10000.00% | 11938.00% | -3.31% | — | 541.60% | 0.00% | 0.00% | 0.02% | -25.37 | -30.21 | — | — |
| CNTA | Centessa Pharmaceuticals … | $22.52 | 3.02B | +60% | — | — | — | -7.88 | 4.63 | — | -6.73 | -25.25 | 4.63 | 0.00% | — | — | -73.93% | -398.61% | -50.32% | 0.29 | -19.93 | 9.25 | 9.09 | 1.20 | 3121.00% | -10000.00% | -1148.00% | -7.65% | -2.45 | -281.71% | 0.00% | 0.00% | 11.98% | -7.43 | -10.51 | — | 3.81 |
| CRNX | Crinetics Pharmaceuticals… | $42.53 | 4.01B | +31% | -56% | — | — | -8.22 | 3.86 | 705.95 | -6.17 | -24.08 | 3.86 | 80.15% | -9534.48% | -8585.18% | -40.17% | -2936.77% | -36.34% | 0.05 | — | 12.32 | 12.09 | 0.11 | 3415.00% | 42166.00% | 6695.00% | -10.03% | -4.44 | -2180.46% | 0.00% | 0.00% | 0.00% | -5.51 | -7.42 | 525.26 | 14.87 |
| IMVT | Immunovant, Inc. | $23.60 | 4.11B | — | — | — | — | -6.14 | 3.59 | — | -4.18 | -13.59 | 3.59 | 0.00% | — | — | -62.46% | 3667.16% | -57.36% | 0.00 | — | 11.16 | 10.42 | 1.63 | 4521.00% | — | 7552.00% | -14.82% | -5.47 | 3152.27% | 0.00% | 0.00% | 3.09% | -4.17 | -4.85 | — | 19.16 |
| KYMR | Kymera Therapeutics, Inc. | $59.89 | 4.3B | -13% | -28% | -100% | -51% | -24.42 | 4.81 | 193.97 | -22.56 | -102.50 | 4.81 | 100.00% | -891.33% | -794.39% | -25.78% | -55.98% | -22.89% | 0.05 | -1403.21 | 10.47 | 10.19 | 0.91 | 2383.00% | -1672.00% | 1302.00% | -3.08% | -2.80 | -37.55% | 0.00% | 0.00% | 3.19% | -19.57 | -29.18 | 174.43 | 27.01 |
| NAMS | NewAmsterdam Pharma Compa… | $38.13 | 4.29B | +8% | -60% | — | +88% | — | 5.50 | 166.90 | -12.87 | — | 5.50 | 99.74% | -1002.90% | -905.74% | 0.00% | 1564.53% | 0.00% | 0.00 | — | 7.88 | 7.69 | 2.02 | -3164.00% | -5061.00% | -704.00% | -3.94% | -1.72 | 1026.20% | 0.00% | — | 0.00% | -13.82 | -21.07 | 138.63 | 24.84 |
| PRAX | Praxis Precision Medicine… | $164.64 | 3.47B | -20% | — | — | — | -24.53 | 8.47 | — | -22.57 | -76.60 | 8.47 | 0.00% | — | — | -45.83% | -195.82% | -42.68% | 0.00 | — | 10.22 | 10.03 | 1.18 | 3203.00% | -10000.00% | 8908.00% | -3.35% | -4.17 | -149.55% | 0.00% | 0.00% | 1.92% | -20.97 | -27.46 | — | 72.54 |
| SLNO | Soleno Therapeutics, Inc. | $46.87 | 2.49B | — | -59% | -78% | — | 99.43 | 4.61 | 10.91 | 62.51 | — | 4.66 | 98.58% | 7.85% | 10.97% | 6.01% | 19.44% | 4.67% | 0.01 | 2.73 | 5.80 | 5.44 | -2.38 | -10890.00% | — | -16741.00% | 2.25% | 0.76 | 60.75% | 0.00% | 0.00% | 6.38% | 118.68 | 37.97 | 9.32 | 10.94 |
| VKTX | Viking Therapeutics, Inc. | $36.47 | 4.12B | — | — | — | — | -10.44 | 5.88 | — | -7.76 | -4.84 | 5.88 | 0.00% | — | — | -47.34% | 896.45% | -44.29% | 0.00 | -7023.96 | 9.33 | 9.21 | 0.42 | 21584.00% | — | 21745.00% | -7.42% | -3.64 | 635.14% | 0.00% | 0.00% | 3.73% | -7.76 | -10.95 | — | 27.00 |
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
- CEO
- Andrew Cheng
- Employees
- 69
- Beta
- -0.41
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).